Intellia Therapeutics, Inc.

NTLANASDAQHealthcare● Active

$13.48

$-0.06(-0.44%)

Market Cap$1.5B

P/E Ratio—

52W High$28.25

52W Low$7.31

Avg Volume5.4M

Open$13.83

Beta1.81

Overview

Intellia Therapeutics, Inc. (NTLA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · NTLA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.10

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 9%Active transactions only · RSU vesting excluded91% Sell ↓

Intellia Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

NTLA insider buying and selling by quarter

NTLA insider selling · NTLA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

947K473K0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · NTLA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

NTLA executive sell shares · NTLA board member insider trading · NTLA insider trading SEC filing

Showing 64 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Mar 1, 2026	LEONARD JOHN M President and CEO · Director	Award	156,400	—	—	1,169,739	Form 4
Mar 1, 2026	BASTA JAMES EVP, General Counsel	Award	46,080	—	—	158,005	Form 4
Mar 2, 2026	BASTA JAMES EVP, General Counsel	Sale	1,211	$13.78	$17K	156,794	Form 4
Mar 1, 2026	Lebwohl David EVP, Chief Medical Officer	Award	9,943	—	—	131,192	Form 4
Mar 1, 2026	Dulac Edward J III EVP, Chief Financial Officer	Award	61,280	—	—	160,963	Form 4
Mar 1, 2026	Schultes Birgit C EVP, Chief Scientific Officer	Award	39,200	—	—	137,733	Form 4
Mar 1, 2026	Clark Eliana EVP, Chief Technical Officer	Award	7,353	—	—	94,471	Form 4
Mar 2, 2026	Clark Eliana EVP, Chief Technical Officer	Sale	607	$13.78	$8K	93,864	Form 4
Mar 1, 2026	Dube Michael P VP, Chief Accounting Officer	Award	17,250	—	—	69,527	Form 4
Jan 5, 2026	LEONARD JOHN M President and CEO · Director	Sale	34,146	$9.21	$314K	1,013,339	Form 4
Jan 5, 2026	Schultes Birgit C EVP, Chief Scientific Officer	Sale	8,508	$9.21	$78K	98,533	Form 4
Jan 5, 2026	BASTA JAMES EVP, General Counsel	Sale	10,397	$9.21	$96K	101,528	Form 4
Jan 5, 2026	Cohen Fred E Director	Purchase	150,000	$9.35	$1.40M⚡	207,453	Form 4
Jan 5, 2026	Lebwohl David EVP, Chief Medical Officer	Sale	11,903	$9.21	$110K	121,249	Form 4
Jan 5, 2026	Clark Eliana EVP, Chief Technical Officer	Sale	9,515	$9.21	$88K	87,118	Form 4
Jan 5, 2026	Dulac Edward J III EVP, Chief Financial Officer	Sale	6,379	$9.21	$59K	99,683	Form 4
Jan 5, 2026	Dube Michael P VP, Chief Accounting Officer	Sale	2,989	$9.21	$28K	52,277	Form 4
Dec 11, 2025	LEONARD JOHN M President and CEO · Director	Option	49,959	$6.83	$341K	1,127,074	Form 4
Dec 11, 2025	LEONARD JOHN M President and CEO · Director	Sale	49,959	$9.49	$474K	1,077,115	Form 4
Dec 12, 2025	LEONARD JOHN M President and CEO · Director	Option	8,557	$6.83	$58K	1,047,485	Form 4
Dec 11, 2025	LEONARD JOHN M President and CEO · Director	Sale	32,832	$9.47	$311K	1,044,283	Form 4
Dec 11, 2025	LEONARD JOHN M President and CEO · Director	Sale	5,355	$9.59	$51K	1,038,928	Form 4
Oct 1, 2025	Schultes Birgit C EVP, Chief Scientific Officer	Sale	31	$17.38	$539	105,184	Form 4
Oct 1, 2025	Dube Michael P VP, Chief Accounting Officer	Sale	1,871	$17.38	$33K	55,266	Form 4
Aug 20, 2025	CHASE WILLIAM J Director	Purchase	100,000	$10.03	$1.00M⚡	134,693	Form 4

LEONARD JOHN M

President and CEO · Director

Award

Date

Mar 1

156,400

Price

—

Value

—

View Form 4 on SEC.gov

BASTA JAMES

EVP, General Counsel

Award

Date

Mar 1

46,080

Price

—

Value

—

View Form 4 on SEC.gov

BASTA JAMES

EVP, General Counsel

Sale

Date

Mar 2

1,211

Price

$13.78

Value

$17K

View Form 4 on SEC.gov

Lebwohl David

EVP, Chief Medical Officer

Award

Date

Mar 1

9,943

Price

—

Value

—

View Form 4 on SEC.gov

Dulac Edward J III

EVP, Chief Financial Officer

Award

Date

Mar 1

61,280

Price

—

Value

—

View Form 4 on SEC.gov

Schultes Birgit C

EVP, Chief Scientific Officer

Award

Date

Mar 1

39,200

Price

—

Value

—

View Form 4 on SEC.gov

Clark Eliana

EVP, Chief Technical Officer

Award

Date

Mar 1

7,353

Price

—

Value

—

View Form 4 on SEC.gov

Clark Eliana

EVP, Chief Technical Officer

Sale

Date

Mar 2

607

Price

$13.78

Value

$8K

View Form 4 on SEC.gov

Dube Michael P

VP, Chief Accounting Officer

Award

Date

Mar 1

17,250

Price

—

Value

—

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Sale

Date

Jan 5

34,146

Price

$9.21

Value

$314K

View Form 4 on SEC.gov

Schultes Birgit C

EVP, Chief Scientific Officer

Sale

Date

Jan 5

8,508

Price

$9.21

Value

$78K

View Form 4 on SEC.gov

BASTA JAMES

EVP, General Counsel

Sale

Date

Jan 5

10,397

Price

$9.21

Value

$96K

View Form 4 on SEC.gov

Cohen Fred E

Director

Purchase

Date

Jan 5

150,000

Price

$9.35

Value

$1.40M ⚡

View Form 4 on SEC.gov

Lebwohl David

EVP, Chief Medical Officer

Sale

Date

Jan 5

11,903

Price

$9.21

Value

$110K

View Form 4 on SEC.gov

Clark Eliana

EVP, Chief Technical Officer

Sale

Date

Jan 5

9,515

Price

$9.21

Value

$88K

View Form 4 on SEC.gov

Dulac Edward J III

EVP, Chief Financial Officer

Sale

Date

Jan 5

6,379

Price

$9.21

Value

$59K

View Form 4 on SEC.gov

Dube Michael P

VP, Chief Accounting Officer

Sale

Date

Jan 5

2,989

Price

$9.21

Value

$28K

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Option

Date

Dec 11

49,959

Price

$6.83

Value

$341K

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Sale

Date

Dec 11

49,959

Price

$9.49

Value

$474K

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Option

Date

Dec 12

8,557

Price

$6.83

Value

$58K

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Sale

Date

Dec 11

32,832

Price

$9.47

Value

$311K

View Form 4 on SEC.gov

LEONARD JOHN M

President and CEO · Director

Sale

Date

Dec 11

5,355

Price

$9.59

Value

$51K

View Form 4 on SEC.gov

Schultes Birgit C

EVP, Chief Scientific Officer

Sale

Date

Oct 1

Price

$17.38

Value

$539

View Form 4 on SEC.gov

Dube Michael P

VP, Chief Accounting Officer

Sale

Date

Oct 1

1,871

Price

$17.38

Value

$33K

View Form 4 on SEC.gov

CHASE WILLIAM J

Director

Purchase

Date

Aug 20

100,000

Price

$10.03

Value

$1.00M ⚡

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About NTLA insider trading

NTLA insider trades

Intellia Therapeutics, Inc. (NTLA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including LEONARD JOHN M (President and CEO · Director), Clark Eliana (EVP, Chief Technical Officer), Dube Michael P (VP, Chief Accounting Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. NTLA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Intellia Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

NTLA insider trading · 5 questions

The insiders of Intellia Therapeutics, Inc. (NTLA) include executives and directors such as LEONARD JOHN M (President and CEO · Director), Clark Eliana (EVP, Chief Technical Officer), Dube Michael P (VP, Chief Accounting Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

NTLA board member insider tradingwho are NTLA insidersNTLA insider rosterIntellia Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026